Idiopathic pulmonary fibrosis and sleep disorders: No longer strangers in the night

European Respiratory Review

Volumn 24, Issue 136, 2015, Pages 327-339

  Schiza, Sophia ^a   Mermigkis, Charalampos ^a   Margaritopoulos, George A ^a,b   Daniil, Zoi ^c   Harari, Sergio ^d   Poletti, Venerino ^e   Renzoni, Elizabetta A ^f   Torre, Olga ^d   Visca, Dina ^f   Bouloukaki, Isolde ^a   Sourvinos, George ^a   Antoniou, Katerina M ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b General Hospital of Kavala   (Greece)

^c UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^d IRCCS MULTIMEDICA   (Italy)

^e MORGAGNI PIERANTONI HOSPITAL   (Italy)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; OXYGEN; GENETIC MARKER;

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EPIGENETICS; FIBROSING ALVEOLITIS; HUMAN; HYPOXIA; INTERSTITIAL LUNG DISEASE; NONREM SLEEP; OXYGEN DESATURATION; OXYGEN THERAPY; PATHOGENESIS; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PROGNOSIS; PULMONARY HYPERTENSION; REM SLEEP; REVIEW; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP QUALITY; THERAPY EFFECT; ANOXIA; COMORBIDITY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; LUNG; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTIVE VALUE; PREVALENCE; RISK FACTOR; SLEEP; SLEEP APNEA, OBSTRUCTIVE;

ANOXIA; COMORBIDITY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; LUNG; OXYGEN INHALATION THERAPY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RISK FACTORS; SLEEP; SLEEP APNEA, OBSTRUCTIVE;

EID: 84930454800     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.00009114     Document Type: Review

References (129)

1. 1 Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
2. 2 Margaritopoulos GA, Romagnoli M, Poletti V, et al. Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis. Eur Respir Rev 2012; 21: 48–56.
3. 3 McNicholas WT, Verbraecken J, Marin JM. Sleep disorders in COPD: the forgotten dimension. Eur Respir Rev 2013; 22: 365–375.
4. 4 McNicholas WT. Impact of sleep in COPD. Chest 2000; 117: Suppl. 2, 48S–53S.
5. 5 Chaouat A, Weitzenblum E, Krieger J, et al. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am J Respir Crit Care Med 1995; 151: 82–86.
6. 6 Machado MC, Vollmer WM, Togeiro SM, et al. CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J 2010; 35: 132–137.
7. 7 King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
8. 8 Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
9. 9 Mermigkis C, Bouloukaki I, Schiza SE. Obstructive sleep apnea in patients with interstitial lung diseases: past and future. Sleep Breath 2013; 17: 1127–1128.
10. 10 Rasche K, Orth MJ. Sleep and breathing in idiopathic pulmonary fibrosis. Physiol Pharmacol 2009; 60: Suppl. 5, 13–14.
11. 11 Agarwal S, Richardson B, Krishnan V, et al. Interstitial lung disease and sleep: what is known? Sleep Med 2009; 10: 947–951.
12. 12 American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277–304.
13. 13 American Academy of Sleep Medicine. The AASM Manual for the scoring of sleep and associated events. Rules, Terminology and Technical Specifications. Westchester, AASM, 2014.
14. 14 Bye P, Issa F, Berthon-Jones M, et al. Studies of oxygenation during sleep in patients with interstitial lung disease. Am Rev Respir Dis 1984; 129: 27–32.
15. 15 Perez-Padilla R, West P, Lertzman M, et al. Breathing during sleep in patients with interstitial lung disease. Am Rev Respir Dis 1985; 132: 224–229.
16. 16 Mermigkis C, Stagaki E, Amfilochiou A, et al. Sleep quality and associated daytime consequences in patients with idiopathic pulmonary fibrosis. Med Princ Pract 2009; 18: 10–15.
17. 17 McNicholas W, Coffey M, Fitzgerald M. Ventilation and gas exchange during sleep in patients with interstitial lung disease. Thorax 1986; 41: 777–782.
18. 18 Mermigkis C, Chapman J, Golish J, et al. Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis. Lung 2007; 185: 173–178.
19. 19 Aronson RM, Carley DW, Onal E. Upper airway muscle activity and the thoracic volume dependence of upper airway resistance. J Appl Physiol 1991; 70: 430–438.
20. 20 Sériès F, Cormier Y, Lampron N, et al. Increasing the functional residual capacity may reverse obstructive sleep apnea. Sleep 1988; 11: 349–353.
21. 21 Sériès F, Cormier Y, Lampron N, et al. Influence of lung volume in sleep apnea. Thorax 1989; 44: 52–57.
22. 22 Heinzer RC, Stanchina ML, Malhotra A, et al. Lung volume and continuous positive airway pressure requirements in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 114–117.
23. 23 Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009; 136: 772–778.
24. 24 Mermigkis C, Stagaki E, Tryfon S, et al. How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis? Sleep Breath 2010; 14: 387–390.
25. 25 Pihtili A, Bingol Z, Kiyan E, et al. Obstructive sleep apnea is common in patients with interstitial lung disease. Sleep Breath 2013; 17: 1281–1288.
26. 26 Young T, Shahar E, Nieto FJ, et al. Predictors of sleep-disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med 2002; 162: 893–900.
27. 27 Lederer DJ, Jelic S, Bhattacharya J, et al. Is obstructive sleep apnea a cause of idiopathic pulmonary fibrosis? Arch Pathol Lab Med 2012; 136: 470.
28. 28 Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch Pathol Lab Med 2012; 136: 591–600.
29. 29 Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378–1384.
30. 30 Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19–25.
31. 31 Mermigkis C, Mermigkis D, Varouchakis G, et al. CPAP treatment in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea—therapeutic difficulties and dilemmas. Sleep Breath 2012; 16: 1–3.
32. 32 Mermigkis C, Bouloukaki I, Antoniou KM, et al. CPAP therapy in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea: Does it offer a better quality of life and sleep? Sleep Breath 2013; 17: 1137–1143.
33. 33 Kolilekas L, Manali E, Vlami KA, et al. Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J Clin Sleep Med 2013; 9: 593–601.
34. 34 Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath 2015; 19: 385–391.
35. 35 Campen MJ, Shimoda LA, O’Donnell CP. Acute and chronic cardiovascular effects of intermittent hypoxia in C57BL/6J mice. J Appl Physiol 2005; 99: 2028–2035.
36. 36 Fagan KA. Pulmonary hypertension in mice intermittent hypoxia. J Appl Physiol 2001; 90: 2502–2507.
37. 37 McGuire M, Bradford A. Chronic intermittent hypercapnic hypoxia increases pulmonary arterial pressure and haematocrit in rats. Eur Respir J 2001; 18: 279–285.
38. 38 Wang Z, Li AY, Guo QH, et al. Effects of cyclic intermittent hypoxia on ET-1 responsiveness and endothelial dysfunction of pulmonary arteries in rats. PLoS One 2013; 8: e58078.
39. 39 Sajkov D, McEvoy RD. Obstructive sleep apnea and pulmonary hypertension. Prog Cardiovasc Dis 2009; 51: 363–370.
40. 40 Minai OA, Ricaurte B, Kaw R, et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 2009; 104: 1300–1306.
41. 41 Arias MA, Rio FG, Fernandez AA, et al. Pulmonary hypertension in obstructive sleep apnoea: Effects of continuous positive airway pressure. Eur Heart J 2006; 27: 1106–1113.
42. 42 Sajkov D, Wang T, Saunders NA, et al. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2002; 165: 152–158.
43. 43 Dumitrascu R, Tiede H, Eckermann J, et al. Sleep apnea in precapillary pulmonary hypertension. Sleep Med 2013; 14: 247–251.
44. 44 Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008; 76: 288–294.
45. 45 Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393–2399.
46. 46 Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746–752.
47. 47 Corte TJ, Wort SJ, Gatzoulis MA, et al. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 2009; 64: 883–888.
48. 48 Modrykamien AM, Gudavalli R, McCarthy K, et al. Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis. Respir Care 2010; 55: 584–588.
49. 49 Harari S. Out of proportion pulmonary hypertension: a paradigm for rare diseases. Chest 2012; 142: 1087–1088.
50. 50 Clark M, Cooper B, Singh S, et al. A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Thorax 2001; 56: 482–486.
51. 51 Corte TJ, Wort SJ, Talbot S, et al. Elevated nocturnal desaturation index predicts mortality in interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29: 41–50.
52. 52 Hira HS, Sharma RK. Study of oxygen saturation, breathing pattern and arrhythmias in patients of interstitial lung disease during sleep. Ind J Chest Dis Allied Sci 1997; 39: 157–162
53. 53 Pitsiou G, Bagalas V, Boutou A, et al. Should we routinely screen patients with idiopathic pulmonary fibrosis for nocturnal hypoxemia? Sleep Breath 2013; 17: 447–448.
54. 54 Turner GA, Lower EE, Corser BC, et al. Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14: 61–64.
55. 55 Aydogdu M, Ciftci B, Firat GS, et al. Interstisyel akciger hastalarinda polisomnografi ile uyku ozelliklerinin degerlendirilmesi [Assessment of sleep with polysomnography in patients with interstitial lung disease]. Tuberk Toraks 2006; 54: 213–221.
56. 56 Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 650–656.
57. 57 Corte TJ, Wort SJ, Gatzoulis MA, et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010; 36: 819–825.
58. 58 Corte TJ, Keir GJ, Dimopoulos K, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2014; 190: 208–217.
59. 59 Hudgel DW, Martin RJ, Capehart M, et al. Contribution of hypoventilation to sleep oxygen desaturation in chronic obstructive pulmonary disease. J Appl Physiol 1983; 55: 669–677.
60. 60 Fletcher EC, Gray BA, Levin DC. Nonapneic mechanisms of arterial oxygen desaturation during rapid-eye-movement sleep. J Appl Physiol 1983; 54: 632–639.
61. 61 Coccagna G, Lugaresi E. Arterial blood gases and pulmonary and systemic arterial pressure during sleep in chronic obstructive pulmonary disease. Sleep 1978; 1: 117–124.
62. 62 Boysen PG, Block AJ, Wynne JW, et al. Nocturnal pulmonary hypertension in patients with chronic obstructive pulmonary disease. Chest 1979; 76: 536–542.
63. 63 Weitzenblum E, Muzet A, Ehrhart M, et al. Variations nocturnes des gaz du sang et de la pression artérielle pulmonaire chez les bronchitiques chroniques insuffisants respiratoires [Nocturnal changes in blood gases and pulmonary arterial pressure in chronic bronchitis patients with respiratory insufficiency]. Nouv Presse Med 1982; 11: 1119–1122.
64. 64 Fletcher EC, Levin DC. Cardiopulmonary hemodynamics during sleep in subjects with chronic obstructive pulmonary disease. The effect of short- and long-term oxygen. Chest 1984; 85: 6–14.
65. 65 Raeside DA, Brown A, Patel KR, et al. Ambulatory pulmonary artery pressure monitoring during sleep and exercise in normal individuals and patients with COPD. Thorax 2002; 57: 1050–1053.
66. 66 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Ann Intern Med 1980; 93: 391–398.
67. 67 Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681–686.
68. 68 Weitzenblum E, Sautegeau A, Ehrhart M, et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131: 493–498.
69. 69 Zieliński J, Tobiasz M, Hawryłkiewicz I, et al. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 1998; 113: 65–70.
70. Crockett AJ, Cranston JM, Antic N. Domiciliary oxygen for interstitial lung disease. Cochrane Database Syst Rev 2001; CD002883.
71. 71 Lubin M, Chen H, Elicker B, et al. A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Chest 2014; 145: 1333–1338.
72. 72 Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95.
73. 73 Shih JL, Malhotra A. Could vitamins be helpful to patients with sleep apnea? Chest 2011; 139: 237–238.
74. 74 Antoniou KM, Margaritopoulos GA, Tomassetti S, et al. Interstitial lung disease. Eur Respir Rev 2014; 23: 40–54.
75. 75 Antoniou KM, Symvoulakis EK, Margaritopoulos GA, et al. Early diagnosis of IPF: time for a primary-care case-finding initiative? Lancet Respir Med 2014; 2: e1.
76. 76 Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748.
77. Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013; 5: 205ra136.
78. 78 Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: 67–76.
79. 79 Antoniou KM, Margaritopoulos GA, Siafakas NM. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev 2013; 22: 281–291.
80. 80 Cottin V, Crestani B, Valeyre D, et al. Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines. Eur Respir Rev 2014; 23: 193–214.
81. 81 Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res 2012; 159: 218–227.
82. 82 Vuga LJ, Tedrow JR, Pandit KV, et al. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 189: 966–974.
83. 83 Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356: 1317–1326.
84. 84 Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104: 7552–7557.
85. 85 Mushiroda T, Wattanapokayakit S, Takahashi A, et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet 2008; 45: 654–656.
86. 86 Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008; 105: 13051–13056.
87. 87 Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364: 1503–1512.
88. 88 Zhang Y, Noth I, Garcia JG, et al. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med 2011; 364: 1576–1577.
89. 89 Noth I, Zhang Y, Ma S-F, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013; 1: 309–317.
90. 90 Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 717–723.
91. 91 Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 588–594.
92. 92 Gilani SR, Vuga LJ, Lindell KO, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One 2010; 5: e8959.
93. 93 Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309: 2232–2239.
94. 94 Yang IV, Coldren CD, Leach SM, et al. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 2013; 68: 1114–1121.
95. 95 Taillé C, Grootenboer-Mignot S, Boursier C, et al. Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 759–766.
96. 96 Kahloon RA, Xue J, Bhargava A, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013; 187: 768–775.
97. 97 Chien JW, Richards TJ, Gibson KF, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J 2014; 43: 1430–1438.
98. 98 O’Dwyer DN, Armstrong ME, Trujillo G, et al. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2013; 188: 1442–1450.
99. 99 Montesi SB, Bajwa EK, Malhotra A. Biomarkers of sleep apnea. Chest 2012; 142: 239–245.
100. 100 Lee RN, Kelly E, Nolan G, et al. Disordered breathing during sleep and exercise in idiopathic pulmonary fibrosis and the role of biomarkers. QJM 2015; 108: 315–323.
101. Arnardottir ES, Mackiewicz M, Gislason T, et al. Molecular signatures of obstructive sleep apnea in adults: a review and perspective. Sleep 2009; 32: 447–470.
102. 102 Sato F, Tsuchiya S, Meltzer SJ, et al. MicroRNAs and epigenetics. FEBS J 2011; 278: 1598–1609.
103. 103 Saetrom P, Snove O Jr, Rossi JJ. Epigenetics and microRNAs. Pediatr Res 2007; 61: 17R–23R.
104. 104 Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007; 128: 669–681.
105. 105 Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 2007; 14: 1008–1016.
106. 106 Fischle W. Talk is cheap – cross-talk in establishment, maintenance, and readout of chromatin modifications. Genes Dev 2008; 22: 3375–3382.
107. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693–705.
108. 108 Kampranis SC, Tsichlis PN. Histone demethylases and cancer. Adv Cancer Res 2009; 102: 103–169.
109. 109 Yang IV, Schwartz DA. Epigenetic control of gene expression in the lung. Am J Respir Crit Care Med 2011; 183: 1295–1301.
110. 110 Yang IV. Epigenomics of idiopathic pulmonary fibrosis. Epigenomics 2012; 4: 195–203.
111. Yang IV, Schwartz DA. Epigenetics of idiopathic pulmonary fibrosis. Transl Res 2015; 165: 48–60.
112. 112 Sun X, He Y, Huang C, et al. The epigenetic feedback loop between DNA methylation and microRNAs in fibrotic disease with an emphasis on DNA methyltransferases. Cell Signal 2013; 25: 1870–1876.
113. 113 Sanders YY, Ambalavanan N, Halloran B, et al. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 525–535.
114. 114 Rabinovich EI, Kapetanaki MG, Steinfeld I, et al. Global methylation patterns in idiopathic pulmonary fibrosis. PLoS One 2012; 7: e33770.
115. 115 Kim J, Bhattacharjee R, Khalyfa A, et al. DNA methylation in inflammatory genes among children with obstructive sleep apnea. Am J Respir Crit Care Med 2012; 185: 330–338.
116. 116 Kheirandish-Gozal L, Khalyfa A, Gozal D, et al. Endothelial dysfunction in children with obstructive sleep apnea is associated with epigenetic changes in the eNOS gene. Chest 2013; 143: 971–977.
117. 117 Santangelo S, Scarlata S, Zito A, et al. Genetic background of idiopathic pulmonary fibrosis. Expert Rev Mol Diagn 2013; 13: 389–406.
118. 118 Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 2013; 22: 265–272.
119. 119 Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 2011; 157: 191–199.
120. 120 Nakahara K, Carthew RW. Expanding roles for miRNAs and siRNAs in cell regulation. Curr Opin Cell Biol 2004; 16: 127–133.
121. 121 Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182: 220–229.
122. 122 Liu G, Friggeri A, Yang Y, et al. MiR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207: 1589–1597.
123. 123 Yang S, Banerjee S, de Freitas A, et al. Participation of miR-200 in pulmonary fibrosis. Am J Pathol 2012; 180: 484–493.
124. 124 Yang S, Xie N, Cui H, et al. miR-31 is a negative regulator of fibrogenesis and pulmonary fibrosis. FASEB J 2012; 26: 3790–3799.
125. 125 Dakhlallah D, Batte K, Wang Y, et al. Epigenetic regulation of miR-17∼92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 2013; 187: 397–405.
126. 126 Li P, Zhao GQ, Chen TF, et al. Serum miR-21 and miR-155 expression in idiopathic pulmonary fibrosis. J Asthma 2013; 50: 960–964.
127. 127 Das S, Kumar M, Negi V, et al. MicroRNA-326 regulates profibrotic functions of transforming growth factor-beta in pulmonary fibrosis. Am J Respir Cell Mol Biol 2014; 50: 882–892.
128. 128 Li P, Li J, Chen T, et al. Expression analysis of serum microRNAs in idiopathic pulmonary fibrosis. Int J Mol Med 2014; 33: 1554–1562.
129. 129 Rosas IO, Yang IV. The promise of epigenetic therapies in treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2013; 187: 336–338.